Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Eflornithine hydrochloride by Panbela Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Eflornithine hydrochloride is under clinical development by Panbela Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Eflornithine hydrochloride by Panbela Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Eflornithine hydrochloride is under clinical development by Panbela Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According...
Eflornithine hydrochloride by Panbela Therapeutics for Gastric Cancer: Likelihood of Approval
Eflornithine hydrochloride is under clinical development by Panbela Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData,...
Eflornithine hydrochloride by Panbela Therapeutics for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
Eflornithine hydrochloride is under clinical development by Panbela Therapeutics and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes)....